Mirati Therapeutics, Inc.
NASDAQ: MRTX0.00 n/a
+0.00%(+0.00)
Loading MRTX…
Loading profile data…Frequently asked questions about MRTX
What does Mirati Therapeutics, Inc. (MRTX) do?
Mirati Therapeutics, Inc. is a U.S.-based biotechnology firm operating at the clinical stage, committed to identifying and developing treatments that target the genetic and immunological factors driving cancer progression. Its pipeline features MRTX849, a KRAS G12C inhibitor currently undergoing Phase 1/2 clinical trials for a range of malignanc...
Where does MRTX trade?
Mirati Therapeutics, Inc. (MRTX) trades on the NASDAQ Global Select.
What sector is MRTX in?
Mirati Therapeutics, Inc. (MRTX) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Mirati Therapeutics, Inc.?
Charles M. Baum is the chief executive officer of Mirati Therapeutics, Inc. (MRTX).
Where is Mirati Therapeutics, Inc. headquartered?
Mirati Therapeutics, Inc. is headquartered in United States.
Does MRTX pay a dividend?
Mirati Therapeutics, Inc. (MRTX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did MRTX go public?
Mirati Therapeutics, Inc. (MRTX) completed its initial public offering in 2013.